Lumera Receives Purchase Order from HMS for a ProteomicProcessor Biosensor
News May 05, 2006
Lumera Corporation has announced that it had received a purchase order from Harvard Medical School (HMS) for its beta ProteomicProcessor™ Biosensor instrument.
"To have an organization of Harvard Medical School's standing purchase one of our beta instruments is extremely gratifying," said Dr. Tim Londergan, Director of Lumera's Bioscience Business Unit.
"We look forward to demonstrating our instrument's capability with Dr. LaBaer's cancer biomarker platform and believe that data from this collaboration will enhance our value proposition with pharmaceutical customers."
As previously announced, Lumera's strategy in this arena is to place five beta units with highly respected, world renowned research organizations to demonstrate and establish new applications, which take advantage of the instrument's unprecedented throughput.
This purchase order from HMS is the second placement of the biosensor.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.